Interesting thing is that every single of the carcinogenic medicines are made in China and also by the same company named as Zhejiang Huahai Pharmaceuticals Co. Ltd.
The recalled medications include Valsartan Tablets manufactured by Major Pharmaceuticals, Solco Healthcare, and Teva Pharmaceuticals, as well as Valsartan/Hydrochlorothiazide Tablets from Solco Healthcare and Teva Pharmaceuticals.
"We have carefully assessed the valsartan-containing medications sold in the United States, and we've found that the valsartan sold by these specific companies does not meet our safety standards".
A request for a class-action suit filed in the Montreal courthouse on Monday wants the manufacturers of a recalled heart medication, valsartan, to pay damages to Quebecers who took the drug. To determine if you're medication has been recalled, look at the drug name and company name on the label of your prescription bottle.
Mike Scribner, a pharmacist at Collier Drug Stores, advises those patients to contact their pharmacist for advice.
He advised patients not to stop taking valsartan drugs without the doctor's permission, warning that going off medication without supervision could be unsafe.
The products subject to this recall were distributed nationwide to wholesale and retail facilities, including hospitals and pharmacies.
The company did not answer AFP calls seeking comment.
The ministry revealed that other products that contain the active substance Valsartan manufactured by other companies are safe and are not included in the withdrawal process. "Switch options are available for a hypertension patient".
The ordeal has reignited concerns regarding the safety of importing drugs into the U.S.
Worryingly, because valsartan is used to treat serious medical conditions such as blood pressure, patients taking drugs containing the active component can not simply stop taking their medication.
Solco declined comment, but in a news release, acknowledged that the recall stemmed from detection of a trace amount of NDMA.
The European Medicines Agency (EMA) first issued an alert on July 5 over supplies of the active ingredient valsartan produced by Zhejiang Huahai Pharmaceutical Company, based in eastern China and listed on Shanghai's stock exchange. The medicines which were said to contain N-nitrosodimethyamine as it is suspected to contain human carcinogen.